quinoxalines has been researched along with Carcinoma in Situ in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Janakiram, NB; Lightfoot, S; Madka, V; Mohammed, A; Pathuri, G; Rao, CV; Ritchie, R; Singh, A; Stratton, N; Suen, C | 1 |
1 other study(ies) available for quinoxalines and Carcinoma in Situ
Article | Year |
---|---|
Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.
Topics: Adenocarcinoma; Animals; Benzodiazepinones; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Chemoprevention; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Quinoxalines; Receptor, Cholecystokinin B; Signal Transduction; Sulfonamides | 2019 |